MaxCyte Stock (MXCT) Gains On Bullish New Analyst Coverage

MaxCyte’s stock (NASDAQ: MXCT) has given holders a painful start to the year, with a decline of 44% YTD seeing the company trade 86% down since the listing less than five years ago. Trading up 2.9% today, MXCT has been given a boost by some new analyst coverage, and a lofty price target.

The initiation of coverage by Stephens, with an “Overweight” rating and a $6 price target is a rare ray of light for bulls. This vote of confidence hinges on MaxCyte’s ongoing investments in expanding its market reach.

According to Stephens’ analysts, these investments, while still in their early stages, hold the key to unlocking substantial long-term revenue growth.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

MaxCyte’s core business revolves around providing cell engineering solutions that are critical for the development of advanced therapies, particularly in the fields of cell and gene therapy. The company’s technology is used by a wide range of biopharmaceutical companies and academic institutions, positioning it at the forefront of a rapidly evolving field.

The collaboration with Ori Biotech, announced in June, exemplifies this strategy. By integrating MaxCyte’s ExPERT™ platform with Ori Biotech’s IRO® platform, the partnership aims to optimize the yield and reduce the manufacturing timelines for gene-edited T cells. This collaboration directly addresses a key bottleneck in the autologous cellular therapy space, potentially making these life-saving treatments more accessible and affordable.

Despite these positive developments, MaxCyte is currently unprofitable, with a trailing twelve-month (ttm) earnings per share of approximately -$0.40 and a net income (ttm) of around -$41.79 million.

This underscores the company’s reliance on continued revenue growth and efficient cost management to achieve profitability.